These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 31826177)

  • 21. ERG rearrangement is associated with prostate cancer-related death in Chinese prostate cancer patients.
    Qi M; Yang X; Zhang F; Lin T; Sun X; Li Y; Yuan H; Ren Y; Zhang J; Qin X; Han B
    PLoS One; 2014; 9(2):e84959. PubMed ID: 24516518
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Deletion of 8p is an independent prognostic parameter in prostate cancer.
    Kluth M; Amschler NN; Galal R; Möller-Koop C; Barrow P; Tsourlakis MC; Jacobsen F; Hinsch A; Wittmer C; Steurer S; Krech T; Büscheck F; Clauditz TS; Beyer B; Wilczak W; Graefen M; Huland H; Minner S; Schlomm T; Sauter G; Simon R
    Oncotarget; 2017 Jan; 8(1):379-392. PubMed ID: 27880722
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transcriptional landscape of PTEN loss in primary prostate cancer.
    Imada EL; Sanchez DF; Dinalankara W; Vidotto T; Ebot EM; Tyekucheva S; Franco GR; Mucci LA; Loda M; Schaeffer EM; Lotan T; Marchionni L
    BMC Cancer; 2021 Jul; 21(1):856. PubMed ID: 34311724
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PTEN and ERG detection in multiparametric magnetic resonance imaging/ultrasound fusion targeted prostate biopsy compared to systematic biopsy.
    Baumgartner E; Del Carmen Rodriguez Pena M; Eich ML; Porter KK; Nix JW; Rais-Bahrami S; Gordetsky J
    Hum Pathol; 2019 Aug; 90():20-26. PubMed ID: 31075299
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intraductal carcinoma of the prostate in the absence of high-grade invasive carcinoma represents a molecularly distinct type of in situ carcinoma enriched with oncogenic driver mutations.
    Khani F; Wobker SE; Hicks JL; Robinson BD; Barbieri CE; De Marzo AM; Epstein JI; Pritchard CC; Lotan TL
    J Pathol; 2019 Sep; 249(1):79-89. PubMed ID: 30993692
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cysteine- rich secretory protein 3 (CRISP3), ERG and PTEN define a molecular subtype of prostate cancer with implication to patients' prognosis.
    Al Bashir S; Alshalalfa M; Hegazy SA; Dolph M; Donnelly B; Bismar TA
    J Hematol Oncol; 2014 Mar; 7():21. PubMed ID: 24606912
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Loss of PTEN expression in ERG-negative prostate cancer predicts secondary therapies and leads to shorter disease-specific survival time after radical prostatectomy.
    Lahdensuo K; Erickson A; Saarinen I; Seikkula H; Lundin J; Lundin M; Nordling S; Bützow A; Vasarainen H; Boström PJ; Taimen P; Rannikko A; Mirtti T
    Mod Pathol; 2016 Dec; 29(12):1565-1574. PubMed ID: 27562498
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer.
    Bismar TA; Yoshimoto M; Vollmer RT; Duan Q; Firszt M; Corcos J; Squire JA
    BJU Int; 2011 Feb; 107(3):477-85. PubMed ID: 20590547
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Loss of CCAAT-enhancer-binding protein alpha (CEBPA) is linked to poor prognosis in PTEN deleted and TMPRSS2:ERG fusion type prostate cancers.
    Minner S; Lutz J; Hube-Magg C; Kluth M; Simon R; Höflmayer D; Burandt E; Tsourlakis MC; Sauter G; Büscheck F; Wilczak W; Steurer S; Schlomm T; Huland H; Graefen M; Haese A; Heinzer H; Jacobsen F; Hinsch A; Poos A; Oswald M; Rippe K; König R; Schroeder C
    Prostate; 2019 Feb; 79(3):302-311. PubMed ID: 30430607
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunohistochemical expression of mismatch repair proteins (MSH2, MSH6, MLH1, and PMS2) in prostate cancer: correlation with grade groups (WHO 2016) and ERG and PTEN status.
    Albero-González R; Hernández-Llodrà S; Juanpere N; Lorenzo M; Lloret A; Segalés L; Duran X; Fumadó L; Cecchini L; Lloreta-Trull J
    Virchows Arch; 2019 Aug; 475(2):223-231. PubMed ID: 31209634
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer.
    Krohn A; Diedler T; Burkhardt L; Mayer PS; De Silva C; Meyer-Kornblum M; Kötschau D; Tennstedt P; Huang J; Gerhäuser C; Mader M; Kurtz S; Sirma H; Saad F; Steuber T; Graefen M; Plass C; Sauter G; Simon R; Minner S; Schlomm T
    Am J Pathol; 2012 Aug; 181(2):401-12. PubMed ID: 22705054
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PTEN, ERG, SPINK1, and TFF3 Status and Relationship in a Prostate Cancer Cohort from Jordanian Arab Population.
    Al Bashir S; Alorjani MS; Kheirallah K; Al Hamad M; Haddad HK; Al-Dwairy A; Bani-Fawwaz BA; Aldaoud N; Halalsheh O; Amawi S; Matalka II
    Medicina (Kaunas); 2024 Jan; 60(1):. PubMed ID: 38256434
    [No Abstract]   [Full Text] [Related]  

  • 33. The expression profile and heterogeneity analysis of ERG in 633 consecutive prostate cancers from a single center.
    Nie L; Pan X; Zhang M; Yin X; Gong J; Chen X; Xu M; Zhou Q; Chen N
    Prostate; 2019 Jun; 79(8):819-825. PubMed ID: 30900303
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessing the order of critical alterations in prostate cancer development and progression by IHC: further evidence that PTEN loss occurs subsequent to ERG gene fusion.
    Gumuskaya B; Gurel B; Fedor H; Tan HL; Weier CA; Hicks JL; Haffner MC; Lotan TL; De Marzo AM
    Prostate Cancer Prostatic Dis; 2013 Jun; 16(2):209-15. PubMed ID: 23545904
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer.
    Allott EH; Ebot EM; Stopsack KH; Gonzalez-Feliciano AG; Markt SC; Wilson KM; Ahearn TU; Gerke TA; Downer MK; Rider JR; Freedland SJ; Lotan TL; Kantoff PW; Platz EA; Loda M; Stampfer MJ; Giovannucci E; Sweeney CJ; Finn SP; Mucci LA
    Clin Cancer Res; 2020 Mar; 26(5):1086-1093. PubMed ID: 31754047
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Family history of prostate cancer and the incidence of ERG- and phosphatase and tensin homolog-defined prostate cancer.
    Hashim D; Gonzalez-Feliciano AG; Ahearn TU; Pettersson A; Barber L; Pernar CH; Ebot EM; Isikbay M; Finn SP; Giovannucci EL; Lis RT; Loda M; Parmigiani G; Lotan T; Kantoff PW; Mucci LA; Graff RE
    Int J Cancer; 2020 May; 146(10):2694-2702. PubMed ID: 31318977
    [TBL] [Abstract][Full Text] [Related]  

  • 37. p16 upregulation is linked to poor prognosis in ERG negative prostate cancer.
    Burdelski C; Dieckmann T; Heumann A; Hube-Magg C; Kluth M; Beyer B; Steuber T; Pompe R; Graefen M; Simon R; Minner S; Tsourlakis MC; Koop C; Izbicki J; Sauter G; Krech T; Schlomm T; Wilczak W; Lebok P
    Tumour Biol; 2016 Sep; 37(9):12655-12663. PubMed ID: 27444279
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer.
    Reid AH; Attard G; Ambroisine L; Fisher G; Kovacs G; Brewer D; Clark J; Flohr P; Edwards S; Berney DM; Foster CS; Fletcher A; Gerald WL; Møller H; Reuter VE; Scardino PT; Cuzick J; de Bono JS; Cooper CS;
    Br J Cancer; 2010 Feb; 102(4):678-84. PubMed ID: 20104229
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical impact of ERG and PTEN status in prostate cancer patients underwent radical prostatectomy.
    Fragkoulis C; Glykas I; Tzelves L; Stamatakos PV; Papadopoulos G; Stathouros G; Dellis A; Ntoumas K; Kostopoulou A; Deliveliotis C; Papatsoris A
    Arch Ital Urol Androl; 2022 Dec; 94(4):390-395. PubMed ID: 36576468
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Integrated analysis of the genomic instability of PTEN in clinically insignificant and significant prostate cancer.
    Murphy SJ; Karnes RJ; Kosari F; Castellar BE; Kipp BR; Johnson SH; Terra S; Harris FR; Halling GC; Klein JL; Nasir A; Bergstrahl E; Rangel LJ; Sukov WR; Vasmatzis G; Cheville JC
    Mod Pathol; 2016 Feb; 29(2):143-56. PubMed ID: 26612463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.